AlphaMark Advisors’s Editas Medicine EDIT Stock Holding History

AlphaMark Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-154	Closed	-$5K	–	592
2019 Q4	$5K	Hold	154	–	–	﹤0.01%	401
2019 Q3	$4K	Hold	154	–	–	﹤0.01%	409
2019 Q2	$4K	Hold	154	–	–	﹤0.01%	433
2019 Q1	$4K	Hold	154	–	–	﹤0.01%	419
2018 Q4	$4K	Hold	154	–	–	﹤0.01%	398
2018 Q3	$5K	Buy	+154	New	+$4.98K	﹤0.01%	420

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AlphaMark Advisors's EDIT Position: Q1 2020 in Review

AlphaMark Advisors sold out of Editas Medicine (EDIT) in Q1 2020, closing a stake of 154 shares — an estimated $5K sold.

AlphaMark Advisors first reported a position in EDIT in Q3 2018 and held it in 6 quarters. The position peaked at $5K in Q4 2019. 199 funds tracked by Wall St. Rank hold EDIT as of Q1 2020.

AlphaMark Advisors reported no remaining Editas Medicine position as of Q1 2020 after selling out during the quarter.
AlphaMark Advisors sold 154 Editas Medicine shares in Q1 2020, an estimated $5K.
AlphaMark Advisors first reported a position in Editas Medicine in Q3 2018 and held it in 6 quarters.
AlphaMark Advisors's Editas Medicine position peaked at $5K in Q4 2019.
199 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2020.

Based on AlphaMark Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.